Citations

Clear

813 citation(s) found for "He, Helen".

American Association of Endocrine Surgeons Guidelines for Adrenalectomy
Wachtel, Heather , Lee, Cortney, Velázquez‐Fernández, David , Berber, Eren, Hammer, Gary D. , Marko, Jamie , Hughes, Marybeth S., Han, Mi Ah , Smith, Philip W. , Wilhelm, Scott M., Fahey, Thomas J. , McKenzie, Travis J. , Strong, Vivian E. , Yip, Linwah , Duh, Quan‐Yang , Jiménez, Camilo , Sturgeon, Cord , Berber, Eren , Bancos, Irina , Lee, James A. , Morris, Lilah F. , Livhits, Masha Jean , Smith, Philip W., Sylvia, L. , Perrier, Nancy D.

Mayo Clinic

JAMA Surgery | August 17, 2022 | Volume: 157 | Issue: 10 | Pages: 870

10.1001/jamasurg.2022.3544 | PMID 35976622 Get It

ImportanceAdrenalectomy is the definitive treatment for multiple adrenal abnormalities. Advances in technology and genomics and an improved understanding of adrenal pathophysiology have altered operative techniques and indications.ObjectiveTo develop evidence-based recommendations to enhance the appropriate, safe, and effective approaches to adrenalectomy.Evidence ReviewA multidisciplinary panel identified and investigated 7 categories of relevant clinical concern to practicing surgeons. Questions were structured in the framework Population, Intervention/Exposure, Comparison, and Outcome, and a guided review of medical literature from PubMed and/or Embase from 1980 to 2021 was performed. Recommendations were developed using Grading of Recommendations, Assessment, Development and Evaluation methodology and were discussed until consensus, and patient advocacy representation was included.FindingsPatients with an adrenal incidentaloma 1 cm or larger should undergo biochemical testing and further imaging characterization. Adrenal protocol computed tomography (CT) should be used to stratify malignancy risk and concern for pheochromocytoma. Routine scheduled follow-up of a nonfunctional adrenal nodule with benign imaging characteristics and unenhanced CT with Hounsfield units less than 10 is not suggested. When unilateral disease is present, laparoscopic adrenalectomy is recommended for patients with primary aldosteronism or autonomous cortisol secretion. Patients with clinical and radiographic findings consistent with adrenocortical carcinoma should be treated at high-volume multidisciplinary centers to optimize outcomes, including, when possible, a complete R0 resection without tumor disruption, which may require en bloc radical resection. Selective or nonselective α blockade can be used to safely prepare patients for surgical resection of paraganglioma/pheochromocytoma. Empirical perioperative glucocorticoid replacement therapy is indicated for patients with overt Cushing syndrome, but for patients with mild autonomous cortisol secretion, postoperative day 1 morning cortisol or cosyntropin stimulation testing can be used to determine the need for glucocorticoid replacement therapy. When patient and tumor variables are appropriate, we recommend minimally invasive adrenalectomy over open adrenalectomy because of improved perioperative morbidity. Minimally invasive adrenalectomy can be achieved either via a retroperitoneal or transperitoneal approach depending on surgeon expertise, as well as tumor and patient characteristics.Conclusions and RelevanceTwenty-six clinically relevant and evidence-based recommendations are provided to assist surgeons with perioperative adrenal care.
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Haddad, Robert I. , Bischoff, Lindsay , Ball, Douglas W., Bernet, Victor , Blomain, Erik , Busaidy, Naifa L. , Campbell, Michael J. , Dickson, Paxton V. , Ehya, Hormoz, Guo, Theresa , Holt, Shelby , Hunt, Jason P. , Kandeel, Fouad , Lamonica, Dominick , Mandel, Susan J., McIver, Bryan, Raeburn, Christopher D., Rezaee, Rod , Roth, Mara Y. , Scheri, Randall P., Sipos, Jennifer A. , Wang, Thomas N., Wirth, Lori J. , Cassara, Carly J., Darlow, Susan, Haddad, Robert , Duh, Quan‐Yang , Goldner, Whitney Sears , Haymart, Megan R. , Iagaru, Andrei H. , Markovina, Stephanie T. , Ridge, John Andrew , Shah, Jatin P. , Sippel, Rebecca S. , Sturgeon, Cord , Wong, Richard J. , Yeh, Michael W.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 10, 2022 | Volume: 20 | Issue: 8 | Pages: 925-951

10.6004/jnccn.2022.0040 | PMID 35948029 Get It

Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients. Surgery is also the main treatment for medullary thyroid carcinoma, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable. Anaplastic thyroid carcinoma is almost uniformly lethal, and iodine-131 imaging and radioactive iodine cannot be used. When systemic therapy is indicated, targeted therapy options are preferred. This article describes NCCN recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, and surgical management of differentiated thyroid carcinoma (papillary, follicular, Hürthle cell carcinoma).
Phase II Study of Enzalutamide for Patients With Androgen Receptor–Positive Salivary Gland Cancers (Alliance A091404)
Ho, Alan L. , Foster, Nathan R. , Zoroufy, Alexander , Campbell, Jordan D., Price, Katharine A., Adkins, Douglas R. , Bowles, Daniel W. , Kang, Hyunseok , Sherman, Eric J. , Morton, Roscoe F., Nadeem, Zaineb , Katabi, Nora , Münster, Pamela N. , Price, Katharine, Adkins, Douglas , Bowles, Daniel W , Kang, Hyunseok , Burtness, Barbara , Sherman, Eric , Morris, Luc G T , Munster, Pamela , Ho, Alan L , Worden, Francis P. , Burtness, Barbara , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | July 22, 2022 | Volume: 40 | Issue: 36 | Pages: 4240-4249

10.1200/jco.22.00229 | PMID 35867947 Get It

PURPOSE The androgen receptor (AR) is expressed (+) in a subset of salivary gland cancers (SGCs). This phase II trial evaluated the efficacy of the antiandrogen enzalutamide in AR+ SGC. METHODS Patients with locally advanced/unresectable or metastatic AR+ SGCs were enrolled. Enzalutamide (160 mg) was given orally once daily. The primary end point was the best overall response rate per RECIST v1.1 within eight cycles. Confirmed responses in ≥ 5 of 41 patients would be considered promising. Secondary end points were progression-free survival, overall survival, and safety. RESULTS Forty-six patients were enrolled; 30 (65.2%) received prior systemic therapy, including 13 (28.3%) with AR-targeted drugs. Of seven (15.2%) partial responses (PRs), only two (4.3%) were confirmed per protocol and counted toward the primary end point. Twenty-four patients (52.2%) had stable disease; 15 (32.6%) had progression of disease as best response. Twenty-six patients (56.5%) experienced tumor regression in target lesions; 18 (39.1%) had partial response/stable disease ≥ 6 months. Tumor regressions were observed in female patients (5 of 6 [83.3%]) and those who received prior AR– (6 of 13 [46.2%]) or human epidermal growth factor receptor 2–targeted therapies (5 of 8 [62.5%]). Three patients remained on treatment at data cutoff (duration, 32.2-49.8 months). The median progression-free survival was 5.6 months (95% CI, 3.7 to 7.5); the median overall survival was 17.0 months (95% CI, 11.8 to 30.0). The most common adverse events were fatigue, hypertension, hot flashes, and weight loss. Total and free testosterone levels increased by a mean of 61.2% and 48.8%, respectively, after enzalutamide. CONCLUSION Enzalutamide demonstrated limited activity in AR+ SGC, failing to meet protocol-defined success in part because of a lack of response durability. Strategies to enhance the efficacy of antiandrogen therapy are needed.
Novel DNA Methylation Biomarker Panel for Detection of Esophageal Adenocarcinoma and High-Grade Dysplasia
Yu, Ming , Moinova, Helen , Willbanks, Amber, Cannon, Victoria K., Wang, Ting , Carter, Kelly , Kaz, Andrew M. , Reddi, Deepti , Inadomi, John M. , Luebeck, E. Georg , Iyer, Prasad G. , Wang, Jean S. , Shaheen, Nicholas J. , Thota, Prashanti N., Willis, Joseph , LaFramboise, Thomas , Chak, Amitabh , Markowitz, Sanford D. , Moinova, Helen R , Inadomi, John , Luebeck, Georg , Shaheen, Nicholas J , Chak, Amitabh , Grady, William M , Willis, Joseph E , Carter, Kelly , Cannon, Victoria K., Reddi, Deepti , Canto, Marcia Irene , Grady, William M.

Mayo Clinic

Clinical Cancer Research | July 15, 2022 | Volume: 28 | Issue: 17 | Pages: 3761-3769

10.1158/1078-0432.ccr-22-0445 | PMID 35705525 Get It

Abstract Purpose: Current endoscopy-based screening and surveillance programs have not been proven effective at decreasing esophageal adenocarcinoma (EAC) mortality, creating an unmet need for effective molecular tests for early detection of this highly lethal cancer. We conducted a genome-wide methylation screen to identify novel methylation markers that distinguish EAC and high-grade dysplasia (HGD) from normal squamous epithelium (SQ) or nondysplastic Barrett's esophagus (NDBE). Experimental Design: DNA methylation profiling of samples from SQ, NDBE, HGD, and EAC was performed using HM450 methylation arrays (Illumina) and reduced-representation bisulfate sequencing. Ultrasensitive methylation-specific droplet digital PCR and next-generation sequencing (NGS)-based bisulfite-sequencing assays were developed to detect the methylation level of candidate CpGs in independent esophageal biopsy and endoscopic brushing samples. Results: Five candidate methylation markers were significantly hypermethylated in HGD/EAC samples compared with SQ or NDBE (P < 0.01) in both esophageal biopsy and endoscopic brushing samples. In an independent set of brushing samples used to construct biomarker panels, a four-marker panel (model 1) demonstrated sensitivity of 85.0% and 90.8% for HGD and EACs respectively, with 84.2% and 97.9% specificity for NDBE and SQ respectively. In a validation set of brushing samples, the panel achieved sensitivity of 80% and 82.5% for HGD and EAC respectively, at specificity of 67.6% and 96.3% for NDBE and SQ samples. Conclusions: A novel DNA methylation marker panel differentiates HGD/EAC from SQ/NDBE. DNA-methylation–based molecular assays hold promise for the detection of HGD/EAC using esophageal brushing samples.
NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022
Wood, Douglas E. , Kazerooni, Ella A. , Eapen, Georgie A. , Ettinger, David S. , Ferguson, J. Scott , Hou, Lifang , Kadaria, Dipen, Klippenstein, Donald, Lackner, Rudy P., Lennes, Inga T. , Leung, Ann N. , Mazzone, Peter J. , Merritt, Robert E. , Midthun, David E. , Onaitis, Mark W. , Pipavath, Sudhakar, Pratt, Christie, Puri, Varun , Raz, Dan J. , Reddy, Chakravarthy, Reid, Mary E. , Sandler, Kim L. , Tanoue, Lynn, Tong, Betty C. , Wei, Benjamin , Westover, Kenneth D. , Yang, Stephen C. , McCullough, Beth, Hughes, Miranda, Hou, Lifang , Leung, Ann , Aberle, Denise R. , Berman, Abigail T. , Brown, Lisa Marie , Kumar, Rohit , Leard, Lorriana E. , Pratt, Christie, Sands, Jacob , Schabath, Matthew B. , Studts, Jamie L. , Travis, William D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 13, 2022 | Volume: 20 | Issue: 7 | Pages: 754-764

10.6004/jnccn.2022.0036 | PMID 35830884 Get It

The NCCN Guidelines for Lung Cancer Screening recommend criteria for selecting individuals for screening and provide recommendations for evaluation and follow-up of lung nodules found during initial and subsequent screening. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Lung Cancer Screening.
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Mehren, Margaret von , Kane, John M. , Agulnik, Mark , Carr, Janai R. , Connelly, Mary, Ganjoo, Kristen N. , Holder, Ashley M. , Homsi, Jade , Keedy, Vicki L. , Kelly, Ciara M. , Kim, Edward , McCarter, Martin D. , McGarry, Sean V., Mesko, Nathan W. , Meyer, Christian F. , Pappo, Alberto S. , Petersen, Ivy A. , Poppe, Matthew M. , Riedel, Richard F. , Schuetze, Scott M. , Shabason, Jacob E. , Zimel, Melissa N. , Hang, Lisa E., Sundar, Hema, Bergman, Mary Anne, Riedel, Richard F , von Mehren, Margaret , Bui, Marilyn M. , Choy, Edwin , Connelly, Mary, Dry, Sarah , González, Ricardo , Liebner, David A. , Parkes, Amanda , Pollack, Seth M. , Sicklick, Jason Keith , Spraker, Matthew B.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 13, 2022 | Volume: 20 | Issue: 7 | Pages: 815-833

10.6004/jnccn.2022.0035 | PMID 35830886 Get It

Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Soft Tissue Sarcoma provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as retroperitoneal/intra-abdominal STS, desmoid tumors, and rhabdomyosarcoma. This portion of the NCCN Guidelines discusses general principles for the diagnosis and treatment of retroperitoneal/intra-abdominal STS, outlines treatment recommendations, and reviews the evidence to support the guidelines recommendations.
Status of Cardiovascular Health in US Adults and Children Using the American Heart Association’s New “Life’s Essential 8” Metrics: Prevalence Estimates From the National Health and Nutrition Examination Survey (NHANES), 2013 Through 2018
Lloyd‐Jones, Donald M. , Labarthe, Darwin R. , Brewer, LaPrincess C. , Sharma, Garima , Rosamond, Wayne D. , Foraker, Randi E. , Black, Terrie , Anderson, Cheryl A.M. , Brewer, LaPrincess C , Sharma, Garima , Rosamond, Wayne , Foraker, Randi , Anderson, Cheryl , Lloyd-Jones, Donald M , Ning, Hongyan , Grandner, Michael A. , Allen, Norrina B. , Lavretsky, Helen , Perak, Amanda Marma

Mayo Clinic

Circulation | June 29, 2022 | Volume: 146 | Issue: 11 | Pages: 822-835

10.1161/circulationaha.122.060911 | PMID 35766033 Get It

Background: The American Heart Association recently published an updated algorithm for quantifying cardiovascular health (CVH)—the Life’s Essential 8 score. We quantified US levels of CVH using the new score. Methods: We included individuals ages 2 through 79 years (not pregnant or institutionalized) who were free of cardiovascular disease from the National Health and Nutrition Examination Surveys in 2013 through 2018. For all participants, we calculated the overall CVH score (range, 0 [lowest] to 100 [highest]), as well as the score for each component of diet, physical activity, nicotine exposure, sleep duration, body mass index, blood lipids, blood glucose, and blood pressure, using published American Heart Association definitions. Sample weights and design were incorporated in calculating prevalence estimates and standard errors using standard survey procedures. CVH scores were assessed across strata of age, sex, race and ethnicity, family income, and depression. Results: There were 23 409 participants, representing 201 728 000 adults and 74 435 000 children. The overall mean CVH score was 64.7 (95% CI, 63.9–65.6) among adults using all 8 metrics and 65.5 (95% CI, 64.4–66.6) for the 3 metrics available (diet, physical activity, and body mass index) among children and adolescents ages 2 through 19 years. For adults, there were significant differences in mean overall CVH scores by sex (women, 67.0; men, 62.5), age (range of mean values, 62.2–68.7), and racial and ethnic group (range, 59.7–68.5). Mean scores were lowest for diet, physical activity, and body mass index metrics. There were large differences in mean scores across demographic groups for diet (range, 23.8–47.7), nicotine exposure (range, 63.1–85.0), blood glucose (range, 65.7–88.1), and blood pressure (range, 49.5–84.0). In children, diet scores were low (mean 40.6) and were progressively lower in higher age groups (from 61.1 at ages 2 through 5 to 28.5 at ages 12 through 19); large differences were also noted in mean physical activity (range, 63.1–88.3) and body mass index (range, 74.4–89.4) scores by sociodemographic group. Conclusions: The new Life’s Essential 8 score helps identify large group and individual differences in CVH. Overall CVH in the US population remains well below optimal levels and there are both broad and targeted opportunities to monitor, preserve, and improve CVH across the life course in individuals and the population.
Life-Threatening Complications of Influenza vs Coronavirus Disease 2019 (COVID-19) in US Children
Halasa, Natasha , Young, Cameron C. , Newhams, Margaret M. , Nakamura, Mari , Levy, Emily R. , Soma, Vijaya L, Talj, Rana, Fitzgerald, Julie C. , Mack, Elizabeth H. , Schuster, Jennifer E. , Coates, Bria M. , Hall, Mark W. , Schwarz, Adam J. , Kong, Michele, Spinella, Philip C. , Loftis, Laura L. , McLaughlin, Gwenn E., Rowan, Courtney M. , Nofziger, Ryan A. , Babbitt, Christopher , Bowens, Cindy , Flori, Heidi R. , Gertz, Shira J. , Zinter, Matt S. , Hume, Janet R. , Singh, Aalok R. , Crandall, Hillary A, Cullimore, Melissa L. , Patel, Manish M. , Randolph, Adrienne G. , Influenza, for the Pediatric Intensive Care, Investigators, Overcoming COVID-19, Kong, Michele, Gaspers, Mary Glas , Sanders, Ronald C., Irby, Katherine , Peter, Mourani, Harvey, Helen , Osborne, Christina , Sara, Shankman, Mourani, Peter M. , Port, Emily, Van, Kevin A, Carroll, Christopher L. , Tarquinio, Keiko M. , Coates, Bria M, Wellnitz, Kari , Bhoojhawon, Guru , Sullivan, Janice E, Bradford, Tamara T. , Riggs, Becky J. , Randolph, Adrienne G, Chen, Sabrina R., Carroll, Ryan W. , Yager, Phoebe H. , Heidemann, Sabrina M. , Hume, Janet R, Martin, Lora , Malloch, Lacy , Inagaki, Kengo , Schuster, Jennifer E, Kietzman, Abigail , Clouser, Katharine N. , Kleinman, Lawrence C. , Horwitz, Steven M. , Keenaghan, Michael , Doymaz, Sule , Walker, Tracie C. , Hall, Mark W, Lansell, Amanda , Staat, Mary Allen , Carcillo, Joseph A. , Smallcomb, Laura , Halasa, Natasha B, Stewart, Laura S , Romero, Yesenia, Hayek, Haya , Bowens, Cindy, Maamari, Mia , Crandall, Hillary , Smith, Lincoln , Kong, Michele , Young, Cameron C , Randolph, Adrienne G , Levy, Emily R , Spinella, Philip C , Kong, Michele , Hume, Janet R , Staat, Mary A , Gertz, Shira J , Spieker, Andrew J. , Olson, Samantha M. , Amarin, Justin Z. , Moffitt, Kristin , Weiss, Scott L. , Maddux, Aline B. , Schwartz, Stephanie P. , Kong, Michele, Hobbs, Charlotte V. , Bembea, Melania M. , Giuliano, John S. , Cvijanovich, Natalie Z , Thomas, Neal J. , Influenza, for the Pediatric Intensive Care, Investigators, Overcoming COVID-19, Kong, Michele, Typpo, Katri , Michelson, Kelly Nicole , Coates, Bria M, Sullivan, Janice E, Montgomery, Vicki , Havlin, Kevin , Randolph, Adrienne G, Fernandes, Neil D. , Hume, Janet R, Dhanrajani, Anita D. , Schuster, Jennifer E, Hill, Shannon, McCulloh, Russell J. , Li, Simon , Ratner, Adam J. , Dapul, Heda , Harwayne‐Gidansky, Ilana , Hymes, Saul , Hall, Mark W, Shein, Steven L. , Fink, Ericka L. , Halasa, Natasha B, Muñoz, Álvaro Coronado , Bowens, Cindy, McGuire, John K.

Mayo Clinic

Clinical Infectious Diseases | June 19, 2022 | Volume: 76 | Issue: 3 | Pages: e280-e290

10.1093/cid/ciac477 | PMID 35717646 Get It

Abstract Background Clinical differences between critical illness from influenza infection vs coronavirus disease 2019 (COVID-19) have not been well characterized in pediatric patients. Methods We compared demographics, clinical characteristics, and outcomes of US children (aged 8 months to 17 years) admitted to the intensive care or high-acuity unit with influenza or COVID-19. Using mixed-effects models, we assessed the odds of death or requiring life support for influenza vs COVID-19 after adjustment for age, sex, race and Hispanic origin, and underlying conditions including obesity. Results Children with influenza (n = 179) were younger than those with COVID-19 (n = 381; median, 5.2 years vs 13.8 years), less likely to be non-Hispanic Black (14.5% vs 27.6%) or Hispanic (24.0% vs 36.2%), and less likely to have ≥1 underlying condition (66.4% vs 78.5%) or be obese (21.4% vs 42.2%), and a shorter hospital stay (median, 5 days vs 7 days). They were similarly likely to require invasive mechanical ventilation (both 30.2%), vasopressor support (19.6% and 19.9%), or extracorporeal membrane oxygenation (2.2% and 2.9%). Four children with influenza (2.2%) and 11 children with COVID-19 (2.9%) died. The odds of death or requiring life support in children with influenza vs COVID-19 were similar (adjusted odds ratio, 1.30; 95% confidence interval, .78–2.15; P = .32). Conclusions Despite differences in demographics and clinical characteristics of children with influenza or COVID-19, the frequency of life-threatening complications was similar. Our findings highlight the importance of implementing prevention measures to reduce transmission and disease severity of influenza and COVID-19.
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Gradishar, William J. , Moran, Meena S. , Abraham, Jame , Aft, Rebecca , Allison, Kimberly H. , Anderson, Bethany , Burstein, Harold J. , Chew, Helen K. , Dang, Chau T. , Goldstein, Lori J. , Hurvitz, Sara A. , Isakoff, Steven J. , Jankowitz, Rachel C. , Javid, Sara H. , Leitch, Marilyn , Lyons, Janice A., Patel, Sameer A. , Pierce, Lori J. , Rosenberger, Laura H. , Sitapati, Amy M. , Smith, Mary Lou , Stringer-Reasor, Erica , Telli, Melinda L. , Wisinski, Kari B. , Burns, Jennifer L. , Telli, Melinda L , Agnese, Doreen Marie , Elias, Anthony , Giordano, Sharon H. , Goetz, Matthew P. , Krishnamurthy, Jairam , Mortimer, Joanne , Rugo, Hope S. , Smith, Karen L. , Soliman, Hatem Hussein , Ward, John Headley , Young, Jessica S. , Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 17, 2022 | Volume: 20 | Issue: 6 | Pages: 691-722

10.6004/jnccn.2022.0030 | PMID 35714673 Get It

The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The content featured in this issue focuses on the recommendations for overall management of ductal carcinoma in situ and the workup and locoregional management of early stage invasive breast cancer. For the full version of the NCCN Guidelines for Breast Cancer, visit NCCN.org .
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures
Mody, Kabir , Jain, Prerna , El-Refai, Sherif , Azad, Nilofer S. , Baretti, Marina , Shroff, Rachna T. , Kelley, Robin Katie, El-Khouiery, Anthony, Hockenberry, Adam J. , Lau, Denise , El-Khoueiry, Anthony B. , El-Refai, Sherif M , Baretti, Marina , Shroff, Rachna T , Kelley, R Katie , El-Khouiery, Anthony B , Hockenberry, Adam J , Yarchoan, Mark , Zabransky, Daniel J. , Kelley, Robin Kate , Lesinski, Gregory B , Yarchoan, Mark

Mayo Clinic

JCO Precision Oncology | June 8, 2022 | Volume: No volume available | Issue: 6 | Pages: No page available

10.1200/po.21.00510 | PMID 35675577 Get It

PURPOSE Biliary tract cancers (BTCs) are aggressive cancers that carry a poor prognosis. An enhanced understanding of the immune landscape of anatomically and molecularly defined subsets of BTC may improve patient selection for immunotherapy and inform immune-based combination treatment strategies. METHODS We analyzed deidentified clinical, genomic, and transcriptomic data from the Tempus database to determine the mutational frequency and mutational clustering across the three major BTC subtypes (intrahepatic cholangiocarcinoma [IHC], extrahepatic cholangiocarcinoma, and gallbladder cancer). We subsequently determined the relationship between specific molecular alterations and anatomical subsets and features of the BTC immune microenvironment. RESULTS We analyzed 454 samples of BTC, of which the most commonly detected alterations were TP53 (42.5%), CDKN2A (23.4%), ARID1A (19.6%), BAP1 (15.5%), KRAS (15%), CDKN2B (14.2%), PBRM1 (11.7%), IDH1 (11.7%), TERT (8.4%), KMT2C (10.4%) and LRP1B (8.4%), and FGFR2 fusions (8.7%). Potentially actionable molecular alterations were identified in 30.5% of BTCs including 39.1% of IHC. Integrative cluster analysis revealed four distinct molecular clusters, with cluster 4 predominately associated with FGFR2 rearrangements and BAP1 mutations in IHC. Immune-related biomarkers indicative of an inflamed tumor-immune microenvironment were elevated in gallbladder cancers and in cluster 1, which was enriched for TP53, KRAS, and ATM mutations. Multiple common driver genes, including TP53, FGFR2, IDH1, TERT, BRAF, and BAP1, were individually associated with unique BTC immune microenvironments. CONCLUSION BTC subtypes exhibit diverse DNA alterations, RNA inflammatory signatures, and immune biomarkers. The association between specific BTC anatomical subsets, molecular alterations, and immunophenotypes highlights new opportunities for therapeutic development.